Stocktoria
NEUROCRINE BIOSCIENCES INC NBIX
NEUROCRINE BIOSCIENCES INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788.1M | $451.2M | $161.6M | $15.0M |
| R&D expense | — | — | — | — | — | — | — | $160.5M | $121.8M | $94.3M |
| SG&A expense | $1.2B | $1.0B | $887.6M | $752.7M | $583.3M | $433.3M | $354.1M | $248.9M | $169.9M | $68.1M |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M | $163.0M | $72.3M | $36.8M | -$131.4M | -$147.4M |
| Interest expense | — | — | $4.6M | $7.1M | $25.8M | $32.8M | $32.0M | $30.5M | $19.5M | $0 |
| Income tax | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M | -$300.6M | $9.5M | $700,000 | $0 | $0 |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M | -$142.5M | -$141.1M |
| EPS (diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M | $228.5M | $147.0M | $101.4M | -$94.3M | -$106.2M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M | $217.6M | $132.3M | $76.6M | -$101.3M | -$110.3M |
| Cash & equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M | $187.1M | $112.3M | $141.7M | $254.7M | $83.3M |
| Inventory | $69.0M | $57.4M | $38.3M | $35.1M | $30.5M | $28.0M | $17.3M | $10.9M | $1.0M | $0 |
| Total assets | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B | $1.7B | $1.3B | $993.2M | $817.6M | $365.1M |
| Total liabilities | $1.4B | $1.1B | $1.0B | $660.9M | $698.5M | $608.5M | $669.1M | $512.4M | $445.5M | $50.2M |
| Shareholders' equity | $3.3B | $2.6B | $2.2B | $1.7B | $1.4B | $1.1B | $636.9M | $480.8M | $372.2M | $314.9M |
Growth · year-over-year · Revenue CAGR 79.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +21.4% | +24.8% | +26.8% | +31.3% | +8.4% | +32.7% | +74.7% | +179.2% | +977.5% | -24.1% |
| Net income growth | +40.2% | +36.7% | +61.6% | +72.4% | -78.0% | +1000.8% | +75.4% | — | — | — |
| EPS growth | +41.9% | +33.2% | +58.3% | +69.6% | -77.9% | +966.7% | +77.3% | — | — | — |
| Free cash flow growth | +34.4% | +54.1% | +12.0% | +38.5% | +7.1% | +64.5% | +72.7% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.